Skip to main content

From the helm: Immutep’s (ASX:IMM) Executive Director & CEO Marc Voigt

Sophia Mavridis
April 6, 2022

In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.

In this video Marc discusses:

  • (0:40) What IMM does and its key strength in the market
  • (1:27) The impact of the FDA’s recent feedback on its lead product
  • (2:53) IMM’s collaborations with big pharma names like Pfizer & Merck
  • (4:03) When to expect data from its current clinical trials
  • (5:10) What’s coming up for IMM

Note: This interview was filmed on 22 March 2022.

Morning Bell 26 April

Sam Kanaan
April 26, 2024

Morning Bell 24 April

Grady Wulff
April 24, 2024

Morning Bell 23 April

Sam Kanaan
April 23, 2024

Morning Bell 22 April

Grady Wulff
April 22, 2024

Morning Bell 19 April

Sam Kanaan
April 19, 2024

Morning Bell 18 April

Grady Wulff
April 18, 2024

Morning Bell 17 April

Grady Wulff
April 17, 2024

Morning Bell 16 April

Sam Kanaan
April 16, 2024

Morning Bell 15 April

Grady Wulff
April 15, 2024

7 Minutes with 7 Executives

Bell Direct
April 12, 2024